Polidocanol vs STS for Leg Telangiectasia: What Does the Evidence Actually Say?

By Dr. Haroun Gajraj | VeinCare Academy

9th September, 2026

Contents

1. TL;DR (Quick Clinical Summary)

2. The UK Regulatory Landscape: Fibrovein vs Aethoxysklerol

3. Deconstructing the EASI Trial: Regimen vs Inherent Superiority

4. What Older Comparative Literature Tells Us

5. In-Vitro Coagulation & Safety: Why Lab Data Isn’t a Clinical League Table

6. Decision Framework: How to Choose in Everyday Practice

7. What About Routine Pre-Treatment Duplex Ultrasound (DUS)?

8. Watch the Deep Dive: Discussion with Richard Oliver

9. Frequently Asked Questions (FAQ)

10. References

TL;DR

• No Categorical Winner: Polidocanol (Aethoxysklerol) and Sodium Tetradecyl Sulphate (STS / Fibrovein) are both licensed detergent sclerosants in the UK with proven clinical efficacy for isolated C1 telangiectasia and reticular veins.

• The EASI Trial Caveat: While the 2010 EASI trial demonstrated higher patient satisfaction for 0.5% polidocanol compared to 1% STS, the concentrations evaluated were not biologically equivalent. It evaluates two specific regimens—it does not prove intrinsic chemical superiority.

• Lab Data ≠ Clinical Complications: In-vitro research highlights concentration-dependent cellular, microparticle, and platelet modulation. However, laboratory coagulation kinetics do not correlate to real-world complication differentials.

• Technique Over Agent: Rare adverse events (tissue necrosis, extravasation, accidental intra-arterial injection, allergic reactions) reflect injector vigilance and experience, sclerosant concentration selection, and injection accuracy rather than drug choice.

• Practical Choice: You can confidently base your agent selection on patient tolerance, previous clinical response, and injector familiarity.

The UK Regulatory Landscape: Fibrovein vs Aethoxysklerol

Practitioners performing microsclerotherapy for superficial leg telangiectasias (spider or thread veins) in the United Kingdom have access to two licensed detergent sclerosants:

1. Sodium Tetradecyl Sulphate (STS) – marketed as Fibrovein (STD Pharmaceutical) [1].

2. Polidocanol (lauromacrogol 400) – marketed as Aethoxysklerol (Kreussler Pharma) [2].

Both agents disrupt the vascular endothelium to achieve vein clearance. Yet, clinicians frequently debate: is one agent categorically superior in efficacy or safety?

When examining peer-reviewed comparative literature, the clinical reality is nuanced: both drugs are effective, safe in experienced hands, and can be used in everyday practice.

Deconstructing the EASI Trial: Regimen vs Inherent Superiority

The landmark trial most frequently cited in sclerosant debates is the multi-centre, double-blind randomized EASI study (Rabe et al., 2010) [3], which compared polidocanol, STS, and isotonic saline for spider veins and reticular leg veins.

The trial yielded two core observations:

1. Active Sclerosants Outperform Placebo: Both polidocanol and STS showed distinct clinical superiority over isotonic saline in cosmetic clearance and vessel occlusion.

2. Patient Satisfaction Differed: Patients allocated to 0.5% polidocanol reported statistically higher satisfaction and treatment success compared to those receiving 1.0% STS.

The Clinical Nuance

It is easy to misinterpret this second finding as objective proof that polidocanol is inherently a "better" molecule.

However, 0.5% polidocanol and 1.0% STS are not equipotent concentrations. 1.0% STS is a relatively aggressive, potent detergent for isolated telangiectasia and carries a greater potential for local post-sclerotherapy inflammation, matting, or discomfort. Had the trial benchmarked 0.5% polidocanol against 0.2% or 0.5% STS, the outcome might have looked different.

EASI evaluated two fixed dosing protocols, not the fundamental pharmacology of the active molecules.

What Older Comparative Literature Tells Us

Earlier prospective trials—notably those led by Goldman and colleagues [4, 5]—further substantiate that both chemical agents yield excellent cosmetic clearance:

• Goldman (2002): Evaluated polidocanol against sodium tetradecyl sulfate in lower limb veins, showing high clearance rates across cohorts [5].

• Rao, Wildemore, and Goldman (2005): Compared liquid and foam iterations of polidocanol and STS in varicose and telangiectatic veins [4].

While informative, these trials have methodological limitations when applied to modern aesthetic microsclerotherapy: they examined mixed cohorts (CEAP C1 through C2/C3) and combined liquid with foam preparations within identical analyses. They confirm both agents work well, but neither study provides unequivocal, isolated C1 data establishing a clear hierarchy.

In-Vitro Coagulation & Safety: Why Lab Data Isn’t a Clinical League Table

Both polidocanol (a non-ionic detergent) and STS (an anionic detergent) produce vascular occlusion through a common pathway:

Endothelial Damage⟶Local Thrombosis⟶Sterile Inflammation⟶Fibrous Obliteration

Extensive benchtop research by Parsi, Connor, and colleagues has mapped how detergents interact with human blood components:

• Cell Death Kinetics: Endothelial desquamation is strictly concentration- and contact-time-dependent. Higher concentrations induce immediate lytic necrosis, whereas lower concentrations require sustained contact to trigger cell death [6].

• Platelet & Clot Modulation: In-vitro studies demonstrate that high-concentration STS can lyse platelets, release cellular microparticles, alter clotting factors, and prolong standard laboratory coagulation assays [7, 8].

• Paradoxical Antiplatelet Action: At sub-lytic concentrations, detergent sclerosants can activate platelets while simultaneously suppressing GPIIb/IIIa receptor activation, paradoxically inhibiting platelet aggregation [9].

Translating Lab Data to the Treatment Room

These hematological phenomena are interesting aspects of pathophysiology, but they do not serve as a clinical risk table. There is no prospective clinical evidence proving that STS produces higher rates of deep vein thrombosis (DVT), systemic thromboembolism, or localized tissue breakdown compared to polidocanol in equivalent clinical settings.

Major complications—such as skin necrosis from extravasation, unintended intra-arterial injection, or hypersensitivity are rare. When they occur, they are almost always related to injection technique, volume, concentration, and pressure, rather than the type of sclerosant used.

Decision Framework: How to Choose in Everyday Practice

With comparative trials showing broad clinical parity, choosing between polidocanol and STS rests on reasoned clinical judgement:

With comparative trials showing broad clinical parity, choosing between polidocanol and STS rests on reasoned clinical judgement across four key factors:

• Patient Comfort & Tolerance: Polidocanol has local anaesthetic properties and may produce less transient stinging upon injection compared to STS.

• Prior Treatment Response: If a patient previously achieved excellent clearance or conversely experienced excessive post-inflammatory hyperpigmentation (PIH) or matting with one agent, alter the regimen accordingly.

• Vessel Calibre & Concentration: Match your concentration to the lumen size. Using lower concentrations (e.g., 0.2%–0.5% polidocanol or 0.1%–0.25% STS) minimizes over-treatment risks in fine telangiectasias.

• Clinician Familiarity: Predictable results stem from reproducible injection technique, good illumination, magnification, and gentle cannulation.What About Routine Pre-Treatment Duplex Ultrasound (DUS)?

Clinicians often link the choice of sclerosant to the requirement for pre-procedure diagnostic imaging. These are separate considerations.

The European Society for Vascular Surgery (ESVS) 2022 Guidelines recommend duplex ultrasound assessment prior to treating reticular veins and telangiectasias to rule out occult truncal saphenous or tributary reflux [10]. Many UK practitioners adopt a different approach, balancing routine DUS against selective scanning based on patient history, examination findings, and clinical risk profiles.

Whichever diagnostic pathway you follow, the choice of sclerosant remains an independent decision.

Watch the Deep Dive: Discussion with Richard Oliver

Want to delve deeper into the pharmacology, clinical aspects, and practical pearls of sclerosant selection?

Watch my in-depth podcast discussion with Richard Oliver—board member of the British Association of Sclerotherapists (BAS) and leading authority in sclerosant pharmacology. We unpack the trial evidence, explore real-world cases, and share practical insights for everyday clinical practice.

👉 Watch the full discussion on YouTube: Polidocanol vs STS with Richard Oliver

Frequently Asked Questions (FAQ)

Is polidocanol clinically superior to STS for spider veins?

No definitive trial proves intrinsic superiority. The widely quoted EASI study demonstrated higher satisfaction with 0.5% polidocanol than with 1.0% STS, but because these doses are not chemically or biologically equivalent, the trial compared two specific dosing regimens rather than the pure potency of the underlying compounds.

Does sodium tetradecyl sulphate (STS) carry a higher DVT or complication risk?

No comparative clinical data supports this. While laboratory studies show distinct concentration-dependent effects on microparticles and clotting pathways, these in-vitro findings have not translated into different clinical complication rates in everyday microsclerotherapy.

Can I mix or switch between polidocanol and STS?

Yes. If a patient experiences resistant telangiectasias or adverse effects like hemosiderin staining with one agent, switching to the alternative sclerosant or adjusting the concentration is an established clinical strategy. But not in the same injection session

What is the most important factor in preventing microsclerotherapy complications?

Injection technique. Meticulous cannulation, strict avoidance of excessive injection pressure, matching concentration to vessel diameter, and careful monitoring for signs of extravasation or tissue blanching are far more important than relying on choice of sclerosing agent alone.

References

1. Fibrovein (sodium tetradecyl sulphate). Summary of Product Characteristics. Electronic Medicines Compendium (emc).

2. Aethoxysklerol (lauromacrogol 400 / polidocanol). Summary of Product Characteristics / Patient Information Leaflet. Electronic Medicines Compendium (emc).

3. Rabe E, Schliephake D, Otto J, Breu FX, Pannier F. Sclerotherapy of telangiectases and reticular veins: a double-blind, randomized, comparative clinical trial of polidocanol, sodium tetradecyl sulphate and isotonic saline (EASI study). Phlebology. 2010;25(3):124–131. doi:10.1258/phleb.2009.009043.

4. Rao J, Wildemore JK, Goldman MP. Double-blind prospective comparative trial between foamed and liquid polidocanol and sodium tetradecyl sulfate in the treatment of varicose and telangiectatic leg veins. Dermatologic Surgery. 2005;31(6):631–635.

5. Goldman MP. Treatment of varicose and telangiectatic leg veins: double-blind prospective comparative trial between aethoxyskerol and sotradecol. Dermatologic Surgery. 2002;28(1):52–55. doi:10.1046/j.1524-4725.2002.01190.x.

6. Kobayashi S, Crooks S, Eckmann DM. Dose- and time-dependent liquid sclerosant effects on endothelial cell death. Dermatologic Surgery. 2006;32(12):1444–1452. doi:10.1111/j.1524-4725.2006.32350.x.

7. Parsi K, Exner T, Connor DE, Ma DD, Joseph JE. In vitro effects of detergent sclerosants on coagulation, platelets and microparticles. European Journal of Vascular and Endovascular Surgery. 2007;34(6):731–740. doi:10.1016/j.ejvs.2007.07.011.

8. Parsi K, Exner T, Low J, Ma DDF, Joseph JE. In vitro effects of detergent sclerosants on clot formation and fibrinolysis. European Journal of Vascular and Endovascular Surgery. 2011;41:267–277.

9. Parsi K, Connor DE, Pilotelle A, Low J, Ma DDF, Joseph JE. Low concentration detergent sclerosants induce platelet activation but inhibit aggregation due to suppression of GPIIb/IIIa activation in vitro. Thrombosis Research. 2012;130(3):472–478. doi:10.1016/j.thromres.2012.03.023.

10. De Maeseneer MG, et al. European Society for Vascular Surgery (ESVS) 2022 Clinical Practice Guidelines on the Management of Chronic Venous Disease of the Lower Limbs. European Journal of Vascular and Endovascular Surgery. 2022;63:184–267. doi:10.1016/j.ejvs.2021.12.024

    About the Author

    

    This educational article is written and regularly reviewed by Dr Haroun Gajraj, a GMC-registered vein specialist who has treated thousands of patients with vein disease and has trained many doctors and nurses in microsclerotherapy, radiofrequency thermocoagulation, and related cosmetic vein procedures. Dr Gajraj is the founder and board member of the British Association of Sclerotherapists. You can view his current GMC registration and independent patient reviews on iWantGreatCare for further information about his clinical background.

    Clinicians remain responsible for assessing each patient, obtaining informed consent, explaining risks and alternatives, and working within the scope of their professional registration and regulatory guidance.

    Subscribe

    For regular updates get my weekly newsletter here

    © VeinCare Academy | Dr. Haroun Gajraj | veincare.academy
    This article is intended for qualified healthcare professionals. All clinical decisions should be based on individual patient assessment, primary medical literature and current professional guidelines.